Back to search
Healthy Volunteers, Pulmonary Arterial Hypertension
Clinical trial pipeline · Data from ClinicalTrials.gov
See which Healthy Volunteers, Pulmonary Arterial Hypertension trials you may qualify forClinical trial pipeline · Data from ClinicalTrials.gov
See which Healthy Volunteers, Pulmonary Arterial Hypertension trials you may qualify forThe purpose of this study is to develop and evaluate the usefulness of hyperpolarized (HP) 129Xe gas MRI for regional assessment of pulmonary function.
A study to learn about the treatment LTP001 in healthy participants (Part A) and in participants with PAH (Part B)
Background: A number of diseases can cause a type of lung injury called pulmonary arterial hypertension (PAH). Most people who develop PAH do not survive more…
F230 is a new Class 1 chemical drug jointly developed by Beijing Contini Pharmaceutical Co., Ltd. for the treatment of pulmonary hypertension (Notification numb…
Pulmonary arterial hypertension (PAH) is a severe disease with a delayed diagnosis and markedly elevated mortality. High-risk populations, such as those with kn…
This is the second single ascending dose study of L608 in healthy participants and is being conducted to evaluate the safety of L608 with dose level ranging fro…
This study will examine and test healthy volunteers and patients with pulmonary hypertension to try to learn more about the disease and find better ways to dete…
The objective of this two part study was to demonstrate safety, tolerability, and pharmacokinetics of RT234 in healthy volunteers. This study is also known as…